Versant Capital Management, Inc Ironwood Pharmaceuticals Inc Transaction History

Versant Capital Management, Inc

$431 Million
Q3 2024

A detailed history of Versant Capital Management, Inc transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 2,804 shares of IRWD stock, worth $11,524. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,804

Previous 160 1652.5%

Holding current value

$11,524

Previous $1,000 1000.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 07, 2024	BUY	$3.93 - $7.04 $10,390 - $18,613	2,644 Added 1652.5%	2,804 $11,000
Q2 2024 Jul 05, 2024	BUY	$5.58 - $8.61 $558 - $861	100 Added 166.67%	160 $1,000
Q3 2023 Oct 11, 2023	SELL	$8.25 - $11.35 $528 - $726	-64 Reduced 51.61%	60 $0
Q2 2023 Jul 10, 2023	BUY	$10.1 - $11.6 $646 - $742	64 Added 106.67%	124 $1,000
Q3 2022 Dec 30, 2022	SELL	$10.14 - $12.38 $304 - $371	-30 Reduced 33.33%	60 $1,000
Q1 2022 Apr 29, 2022	BUY	$10.61 - $12.88 $318 - $386	30 Added 50.0%	90 $1,000
Q2 2020 Jul 16, 2020	SELL	$9.14 - $11.97 $182 - $239	-20 Reduced 25.0%	60 $0
Q1 2020 Apr 17, 2020	SELL	$8.58 - $14.01 $111 - $182	-13 Reduced 13.98%	80 $0
Q4 2019 Jan 28, 2020	SELL	$8.22 - $14.0 $345 - $588	-42 Reduced 31.11%	93 $1,000
Q3 2019 Oct 18, 2019	BUY	$8.59 - $10.96 $42 - $54	5 Added 3.85%	135 $1,000
Q2 2019 Jul 16, 2019	SELL	$9.8 - $12.89 $156 - $206	-16 Reduced 10.96%	130 $1,000
Q1 2019 Apr 23, 2019	BUY	$8.27 - $12.73 $1,199 - $1,845	145 Added 14500.0%	146 $1,000
Q1 2019 Apr 23, 2019	BUY	$8.27 - $12.73 $8 - $12	1 New	1 $1,000

Others Institutions Holding IRWD

# of Institutions

239

Shares Held

163M

Call Options Held

11.2M

Put Options Held

9.1K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $630M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.

Account

Versant Capital Management, Inc Ironwood Pharmaceuticals Inc Transaction History